Pictet Asset Management Holding SA Sells 1,956 Shares of Natera, Inc. $NTRA

Pictet Asset Management Holding SA cut its holdings in shares of Natera, Inc. (NASDAQ:NTRA) by 3.8% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 48,927 shares of the medical research company’s stock after selling 1,956 shares during the period. Pictet Asset Management Holding SA’s holdings in Natera were worth $9,785,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Coatue Management LLC lifted its stake in Natera by 1,446.1% during the 4th quarter. Coatue Management LLC now owns 2,633,334 shares of the medical research company’s stock valued at $603,270,000 after acquiring an additional 2,463,008 shares during the period. Wellington Management Group LLP boosted its holdings in shares of Natera by 94.7% during the 4th quarter. Wellington Management Group LLP now owns 4,976,325 shares of the medical research company’s stock valued at $1,140,026,000 after acquiring an additional 2,420,263 shares during the last quarter. Norges Bank bought a new stake in shares of Natera in the fourth quarter worth approximately $372,398,000. JPMorgan Chase & Co. grew its stake in shares of Natera by 10.5% in the fourth quarter. JPMorgan Chase & Co. now owns 12,854,334 shares of the medical research company’s stock worth $2,944,800,000 after acquiring an additional 1,225,420 shares during the period. Finally, Franklin Resources Inc. raised its holdings in shares of Natera by 37.5% during the third quarter. Franklin Resources Inc. now owns 2,665,013 shares of the medical research company’s stock valued at $428,987,000 after purchasing an additional 727,366 shares during the last quarter. 99.90% of the stock is currently owned by institutional investors.

Natera Stock Performance

NTRA opened at $279.32 on Friday. The company has a market cap of $40.00 billion, a price-to-earnings ratio of -171.36 and a beta of 1.51. The company’s 50 day moving average is $219.79 and its 200 day moving average is $217.32. Natera, Inc. has a 12-month low of $131.81 and a 12-month high of $279.63.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the stock. Piper Sandler restated an “overweight” rating and set a $249.00 price objective on shares of Natera in a research report on Tuesday, May 12th. Royal Bank Of Canada started coverage on shares of Natera in a research report on Thursday, June 11th. They issued an “outperform” rating and a $275.00 target price for the company. The Goldman Sachs Group started coverage on shares of Natera in a research note on Friday, June 5th. They set a “neutral” rating and a $245.00 target price for the company. William Blair assumed coverage on Natera in a research note on Tuesday, April 14th. They issued an “outperform” rating on the stock. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Natera in a report on Tuesday, April 21st. Three research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $260.33.

Insider Buying and Selling at Natera

In other news, CEO Steven Leonard Chapman sold 41,124 shares of Natera stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $221.03, for a total transaction of $9,089,637.72. Following the transaction, the chief executive officer owned 108,743 shares in the company, valued at $24,035,465.29. This trade represents a 27.44% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Herm Rosenman sold 16,530 shares of the business’s stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $250.00, for a total transaction of $4,132,500.00. Following the sale, the director directly owned 4,250 shares of the company’s stock, valued at approximately $1,062,500. The trade was a 79.55% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 175,872 shares of company stock valued at $38,808,996 in the last quarter. Insiders own 5.05% of the company’s stock.

Natera Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.